Abstract: The present invention concerns compounds and their use to treat cardiovascular disease, renal disease, thrombic disease, stroke, metabolic syndrome, cell proliferation, and ischemic cardiovascular disorders. Compounds of the present invention display significant potency as antagonists of 20-hydroxyeicosatetraenoic acid (20-HETE), and function as anti-hypertensive, anti-inflammatory, or anti-growth agents.
Type:
Grant
Filed:
March 8, 2017
Date of Patent:
July 4, 2023
Assignees:
Board of Regents, The University of Texas System, New York Medical College
Inventors:
John R. Falck, Michal L. Schwartzman, Victor Garcia
Abstract: Methods for inhibiting cell growth, inhibiting DNA polymerase activity, and inhibiting DNA replication and repair are provided. In a method of inhibiting cell growth, a cell, such as a cancer cell, is contacted with zelpolib or a derivative or pharmaceutically acceptable salt thereof. The cell growth can be inhibited in vivo, and in certain embodiments, the cell growth is inhibited in vitro. In a method for inhibiting DNA polymerase activity, a DNA polymerase is contacted with zelpolib or a derivative or pharmaceutically acceptable salt thereof. In certain embodiments, the DNA polymerase is Pol ?. In a method for inhibiting DNA replication and repair, a cell, such as a cancer cell, is contacted with zelpolib or a derivative or pharmaceutically acceptable salt thereof. The DNA replication and repair can be inhibited in vivo, and in certain embodiments, the DNA replication and repair is inhibited in vitro.
Abstract: The present disclosure relates to compositions and methods for restoring endothelial glycocalyx. Exemplary compositions include nanoparticle compositions of preassembled glycocalyx.
Abstract: The present disclosure provides methods for detecting early Lyme disease. The present disclosure provides a biosignature indicative of the presence or absence of Borrelia burgdorferi infection.
Type:
Grant
Filed:
February 17, 2016
Date of Patent:
June 2, 2020
Assignees:
The United States of America, as represented by the Secretary, Department of Health and Human Services, Colorado State University Research Foundation, New York Medical College
Inventors:
John T. Belisle, Claudia R. Molins, Gary P. Wormser
Abstract: Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration cytokines are disclosed and claimed. Methods and compositions for the development of large arteries and vessels are also disclosed and claimed. The present application also discloses and claims methods and media for the growth, expansion, and activation of human cardiac stem cells.
Abstract: The invention provides compositions of adult cardiac vascular progenitor cells (VPCs) and adult cardiac myocyte progenitor cells (MPCs) useful for the treatment of various cardiac conditions. The invention also encompasses methods of generating a biological bypass, repairing damaged myocardium, and treating or preventing hypertensive cardiomyopathy and heart failure with the compositions of the invention. Methods of isolating the cardiac progenitor cells are also disclosed.
Type:
Grant
Filed:
February 2, 2012
Date of Patent:
January 7, 2014
Assignee:
New York Medical College
Inventors:
Piero Anversa, Annarosa Leri, Jan Kajstura
Abstract: Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration of cytokines, variants of cytokines, cardiac stem cells, or combinations thereof are disclosed and claimed. In addition, methods, compositions, and kits for forming coronary vasculature including the administration of cytokines, variants of cytokines, cardiac stem cells, or combinations thereof are described. In particular, administration of variants of hepatocyte growth factor, such as NK1, 1K1, and HP11, are useful for the repair and/or regeneration of damaged myocardium or formation of coronary vasculature. Methods of activating cardiac stem cells in vitro are also disclosed.
Abstract: The invention provides novel methods of reducing transplant rejection and cardiac allograft vasculopathy in humans by employing the implantation of autologous progenitor cells into the transplanted donor heart. The autologous progenitor cells can be vascular progenitor cells (VPCs) and/or myocyte progenitor cells (MPCs) isolated from the recipient's explanted heart. Alternatively, bone marrow progenitor cells (BMPCs) isolated from the recipient may also be used.
Type:
Grant
Filed:
February 27, 2012
Date of Patent:
October 8, 2013
Assignee:
New York Medical College
Inventors:
Piero Anversa, Annarosa Leri, Jan Kajstura
Abstract: The invention provides compositions comprising modified stem cells containing a transgene that affects the expression of at least one gene that inhibits or promotes cardiomyogenesis. In particular, the invention discloses compositions comprising cardiac stem cells, wherein said cardiac stem cells comprise a transgene encoding a microRNA. The compositions of the invention find use in the treatment of cardiovascular disorders, such as myocardial infarction. Methods of repairing damaged myocardium in a subject using the modified stem cells are also disclosed.
Type:
Grant
Filed:
June 4, 2012
Date of Patent:
July 30, 2013
Assignee:
New York Medical College
Inventors:
Toru Hosoda, Piero Anversa, Annarosa Leri, Jan Kajstura
Abstract: The invention provides compositions comprising modified stem cells containing a transgene that affects the expression of at least one gene that inhibits or promotes cardiomyogenesis. In particular, the invention discloses compositions comprising cardiac stem cells, wherein said cardiac stem cells comprise a transgene encoding a microRNA. The compositions of the invention find use in the treatment of cardiovascular disorders, such as myocardial infarction. Methods of repairing damaged myocardium in a subject using the modified stem cells are also disclosed.
Type:
Application
Filed:
June 4, 2012
Publication date:
January 17, 2013
Applicant:
New York Medical College
Inventors:
Toru Hosoda, Piero Anversa, Annarosa Leri, Jan Kajstura
Abstract: Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration of stem cells, such as adult stem cells, optionally with cytokines are disclosed and claimed.
Abstract: The invention provides novel methods of reducing transplant rejection and cardiac allograft vasculopathy in humans by employing the implantation of autologous progenitor cells into the transplanted donor heart. The autologous progenitor cells can be vascular progenitor cells (VPCs) and/or myocyte progenitor cells (MPCs) isolated from the recipient's explanted heart. Alternatively, bone marrow progenitor cells (BMPCs) isolated from the recipient may also be used.
Type:
Application
Filed:
February 27, 2012
Publication date:
August 23, 2012
Applicant:
New York Medical College
Inventors:
Piero ANVERSA, Annarosa LERI, Jan KAJSTURA
Abstract: Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration of cytokines, variants of cytokines, cardiac stem cells, or combinations thereof are disclosed and claimed. In addition, methods, compositions, and kits for forming coronary vasculature including the administration of cytokines, variants of cytokines, cardiac stem cells, or combinations thereof are described. In particular, administration of variants of hepatocyte growth factor, such as NK1, 1K1, and HP11, are useful for the repair and/or regeneration of damaged myocardium or formation of coronary vasculature. Methods of activating cardiac stem cells in vitro are also disclosed.
Abstract: The invention provides compositions of adult cardiac vascular progenitor cells (VPCs) and adult cardiac myocyte progenitor cells (MPCs) useful for the treatment of various cardiac conditions. The invention also encompasses methods of generating a biological bypass, repairing damaged myocardium, and treating or preventing hypertensive cardiomyopathy and heart failure with the compositions of the invention. Methods of isolating the cardiac progenitor cells are also disclosed.
Type:
Application
Filed:
February 2, 2012
Publication date:
August 16, 2012
Applicant:
New York Medical College
Inventors:
Piero ANVERSA, Annarosa Leri, Jan Kajstura
Abstract: The invention provides compositions comprising modified stem cells containing a transgene that affects the expression of at least one gene that inhibits or promotes cardiomyogenesis. In particular, the invention discloses compositions comprising cardiac stem cells, wherein said cardiac stem cells comprise a transgene encoding a microRNA. The compositions of the invention find use in the treatment of cardiovascular disorders, such as myocardial infarction. Methods of repairing damaged myocardium in a subject using the modified stem cells are also disclosed.
Type:
Grant
Filed:
June 9, 2009
Date of Patent:
June 5, 2012
Assignee:
New York Medical College
Inventors:
Toru Hosoda, Piero Anversa, Annarosa Leri, Jan Kajstura
Abstract: The invention provides novel methods of reducing transplant rejection and cardiac allograft vasculopathy in humans by employing the implantation of autologous progenitor cells into the transplanted donor heart. The autologous progenitor cells can be vascular progenitor cells (VPCs) and/or myocyte progenitor cells (MPCs) isolated from the recipient's explanted heart. Alternatively, bone marrow progenitor cells (BMPCs) isolated from the recipient may also be used.
Type:
Grant
Filed:
December 1, 2008
Date of Patent:
February 28, 2012
Assignee:
New York Medical College
Inventors:
Piero Anversa, Annarosa Leri, Jan Kajstura
Abstract: The invention provides compositions of adult cardiac vascular progenitor cells (VPCs) and adult cardiac myocyte progenitor cells (MPCs) useful for the treatment of various cardiac conditions. The invention also encompasses methods of generating a biological bypass, repairing damaged myocardium, and treating or preventing hypertensive cardiomyopathy and heart failure with the compositions of the invention. Methods of isolating the cardiac progenitor cells are also disclosed.
Type:
Grant
Filed:
December 1, 2008
Date of Patent:
February 21, 2012
Assignee:
New York Medical College
Inventors:
Piero Anversa, Annarosa Leri, Jan Kajstura
Abstract: The invention discloses compositions comprising nucleic acid(s) for rapid detection, identification, differentiation, and/or diagnosis of certain Influenza virus A subtypes, e.g., H1N1, H3N2 and A(2009 H1N1)pdm, and methods of use thereof, e.g., Short-run RT-PCR, including an RT-PCR assay kit, comprising the disclosed composition(s).
Type:
Application
Filed:
July 8, 2011
Publication date:
January 19, 2012
Applicant:
New York Medical College
Inventors:
Manojkumar Ramanunninair, Doris J. Bucher
Abstract: Aspects of the invention concern methods for detecting, identifying and evaluating tobacco and tobacco products to determine the potential that these compositions have to contribute to a tobacco-related disease. It is based, at least in part; on the discovery that exposure of pulmonary cells to smoke or smoke condensate obtained from tobacco or tobacco products induces double stranded breaks in cellular DNA, which were efficiently detected using assays that measure the presence, absence, or amount of phosphorylation of the histone, H2AX.
Type:
Application
Filed:
March 28, 2011
Publication date:
September 8, 2011
Applicants:
VECTOR TOBACCO, INC., New York Medical College
Inventors:
Anthony P. Albino, Ellen D. Jorgensen, Frank Traganos, Zbigniew Darzynkiewicz, Wendy Jin
Abstract: Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration of cytokines are disclosed and claimed.